A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

Brief description of study

The purpose of the study is to determine how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Savolitinib is a potent and selective small molecule MET kinase inhibitor with significant antitumour activity. The study drug savolitinib is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health auiputhority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01392
ClinicalTrials.gov Identifier: NCT03592641

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.